Project

Safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative metastatic or locally recurrent breast cancer. A multicenter, randomized phase III trial

Automatically Closed · 2010 until 2013

Hasler-Strub Ursula, Thürlimann Beat, Ruhstaller Thomas, Huober Jens